Skip to content
Optionomics

ESYN earnings analysis

10-Q · Filed November 13, 2026 · Our reading of the company's report

The latest report

The quarter reported revenue of $72,646 and EPS of $(0.15), but the supplied extract does not provide gross margin, operating income, cash flow, balance-sheet, segment, or comparative-period data. The company raised…

Read full summary

The quarter reported revenue of $72,646 and EPS of $(0.15), but the supplied extract does not provide gross margin, operating income, cash flow, balance-sheet, segment, or comparative-period data. The company raised $10,000,000 through an issuance of 20,000,000 shares and warrants for up to 160,000,000 shares, improving near-term funding but creating significant dilution risk. Sentiment is bearish because management reported ineffective disclosure controls as of September 30, 2026, and no quantitative outlook was provided.

Read the original on SEC.gov

Reported figures

Earnings per share
$-0.15

What stood out

  • Completed $10 million financing

    The company completed a financing on August 10, 2026, issuing 20,000,000 common shares and warrants for up to 160,000,000 additional shares for aggregate proceeds of $10,000,000.

  • Potential future warrant proceeds

    The warrants have an exercise price of $0.63 per share and are immediately exercisable for four years from the closing date, potentially providing additional capital if exercised.

  • Quarterly revenue and EPS reported

    The reported quarter included revenue of $72,646 and EPS of $(0.15), although the supplied filing extract does not include comparative income-statement detail.

What to watch

  • Ineffective disclosure controls

    Management concluded that disclosure controls and procedures were not effective as of September 30, 2026, raising the risk that required information may not be recorded, processed, summarized, or reported on a timely basis.

  • Substantial potential dilution

    The August 10, 2026 financing issued 20,000,000 common shares and warrants for up to 160,000,000 additional shares, creating substantial potential dilution to existing holders.

  • Large warrant overhang

    The warrants are exercisable immediately at $0.63 per share and expire four years after closing, which may create selling pressure or limit upside for existing shareholders if exercised.

Management's outlook

The provided 10-Q extract contains no quantitative revenue or EPS outlook; no guidance comparison is available.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.

See every ESYN trade live.

The free pages stop at the last full session. Trader shows every trade as it prints.

Start tracking No card needed.